During the past decade, Yale University School of Medicine, Alzheimer's Disease Research Unit conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 5 clinical trials were completed, i.e. on average, 125% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Yale University School of Medicine, Alzheimer's Disease Research Unit" #1 sponsor was "OPKO Health, Inc." with 2 trials, followed by "Alzheimer's Disease Cooperative Study (ADCS)" with 1 trials sponsored, "FUJIFILM Toyama Chemical Co., Ltd." with 1 trials sponsored, "JANSSEN Alzheimer Immunotherapy Research & Development, LLC" with 1 trials sponsored and "Johns Hopkins Bloomberg School of Public Health" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Yale University School of Medicine, Alzheimer's Disease Research Unit" #1 collaborator was "National Institute on Aging (NIA)" with 3 trials as a collaborator, "Alzheimer's Disease Cooperative Study (ADCS)" with 1 trials as a collaborator, "Alzheimer's Therapeutic Research Institute" with 1 trials as a collaborator, "Amgen" with 1 trials as a collaborator and "Banner Alzheimer's Institute" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Yale University School of Medicine, Alzheimer's Disease Research Unit" are "Alzheimer's Disease" (8 trials), "Alzheimer Disease" (3 trials), "Alzheimers Disease" (1 trials), "Apathy" (1 trials) and "Dyssomnias" (1 trials). Many other conditions were trialed in "Yale University School of Medicine, Alzheimer's Disease Research Unit" in a lesser frequency.

Most popular intervention types in "Yale University School of Medicine, Alzheimer's Disease Research Unit" are "Drug" (10 trials), "Biological" (2 trials), "Other" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Placebo Control" (2 trials), "ACC-001 10 μg/ QS-21 50 μg" (1 trials), "ACC-001 3 μg/ QS-21 50 μg" (1 trials) and "AZD0530 100mg daily" (1 trials). Other intervention names were less common.

The vast majority of trials in "Yale University School of Medicine, Alzheimer's Disease Research Unit" are 12 trials for "All" genders.

Currently, there are NaN active trials in "Yale University School of Medicine, Alzheimer's Disease Research Unit". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Yale University School of Medicine, Alzheimer's Disease Research Unit, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Yale University School of Medicine, Alzheimer's Disease Research Unit, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".